FDA Rejects Novartis Biosimilar App for Amgen Neulasta

Source: Reuters

Jul 19, 2016

The U.S. FDA has declined to approve Novartis' application for a biosimilar copy of Amgen's blockbuster, Neulasta.

Novartis noted briefly in its Q2 report: "Sandoz received a complete response letter from the FDA for biosimilar pegfilgrastim candidate (Neulasta®). We are working with the agency to address remaining questions."

Approved in 2002, Neulasta is used to help reduce the chance of infection due to a low white blood cell count, in people with non-myeloid cancer, who receive chemotherapy that can cause fever and low blood cell count.

Sandoz did not provide further details regarding the complete response letter.

Read the Reuters brief

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments